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Abstract
Background: A high body mass index (BMI) has been associated with reduced semen quality and male
subfecundity, but no studies following obese men losing weight have yet been published. We examined semen
quality and reproductive hormones among morbidly obese men and studied if weight loss improved the
reproductive indicators.
Methods: In this pilot cohort study, 43 men with BMI > 33 kg/m
2 were followed through a 14 week residential
weight loss program. The participants provided semen samples and had blood samples drawn, filled in
questionnaires, and had clinical examinations before and after the intervention. Conventional semen characteristics
as well as sperm DNA integrity, analysed by the sperm chromatin structure assay (SCSA) were obtained. Serum
levels of testosterone, estradiol, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating
hormone (FSH), anti-Müllerian hormone (AMH) and inhibin B (Inh-B) were measured.
Results: Participants were from 20 to 59 years of age (median = 32) with BMI ranging from 33 to 61 kg/m
2.A t
baseline, after adjustment for potential confounders, BMI was inversely associated with sperm concentration (p =
0.02), total sperm count (p = 0.02), sperm morphology (p = 0.04), and motile sperm (p = 0.005) as well as
testosterone (p = 0.04) and Inh-B (p = 0.04) and positively associated to estradiol (p < 0.005). The median (range)
percentage weight loss after the intervention was 15% (3.5 - 25.4). Weight loss was associated with an increase in
total sperm count (p = 0.02), semen volume (p = 0.04), testosterone (p = 0.02), SHBG (p = 0.03) and AMH (p =
0.02). The group with the largest weight loss had a statistically significant increase in total sperm count [193
millions (95% CI: 45; 341)] and normal sperm morphology [4% (95% CI: 1; 7)].
Conclusion: This study found obesity to be associated with poor semen quality and altered reproductive
hormonal profile. Weight loss may potentially lead to improvement in semen quality. Whether the improvement is
a result of the reduction in body weight per se or improved lifestyles remains unknown.
Introduction
The prevalence of overweight and obese individuals is
increasing globally [1] and concern is rising over the
reproductive consequences of male obesity. Male obesity
has been linked to subfecundity [2-4] and a dose-
response relationship between increasing BMI and
subfecundity has been proposed [3]. Furthermore, male
obesity has been associated with abnormal semen char-
acteristics [5-14], although results are conflicting
[15-21]. The hormonal abnormality [22-24] associated
with obesity is likely to play a major role, and although
controversial [25-27], previous studies have shown that
the endocrine abnormalities may be reversed by weight
reduction [28-33].
Several studies have focused on inhibin B (Inh-B)
[34-37], and more recently also anti-Müllerian hormone
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cells, as markers of spermatogenesis [38-40]. Studies
have shown Inh-B to be positively associated with
fecundability [41], and obesity has been shown to be
associated with a decreased level of Inh-B [5,16]. How-
ever, results are conflicting [42,43], and studies on the
association between obesity and AMH are lacking.
It is unclear to what extent obesity affects a man’s
reproductive potential. The existing studies on this sub-
ject are all cross-sectional, a limited design for deriving
causal inferences. There may be a causal link between
male obesity and poor semen quality, however, they may
also share a common aetiological factor. Longitudinal
studies investigating how weight loss affects semen qual-
ity are needed to disentangle these two hypotheses, but
no such studies have yet been published. In this paper,
we present results from a pilot cohort study with pro-
spectively collected data, investigating how obesity and
weight loss affect reproductive hormones including
AMH and Inh-B, conventional semen characteristics as
well as sperm DNA integrity.
Methods
Study population and data collection
Data collection took place from April 2006 to April
2009. Men who participated in a residential weight loss
program in Ebeltoft, Denmark were recruited to this
pilot cohort study. During the data collection period,
men over the age of 18, independent of their weight,
were invited to participate and a total of 107 men were
invited. Forty-four men (41%) accepted the invitation.
O u to ft h e4 4p a r t i c i p a n t s ,2 7m e n( 6 1 % )t o o kp a r ti n
the follow-up at the end of the weight loss program. We
excluded one man diagnosed with Klinefelter’ss y n -
drome, and in the analyses of semen characteristics, two
men with azoospermia were excluded because azoosper-
mia probably is not caused by obesity alone.
The weight loss program, based on a healthy diet and
daily exercise, lasted approximately 14 weeks. Before
and after the weight loss program, the participants had
blood samples drawn, provided semen samples and had
clinical examinations. The clinical examination was per-
formed on site by one investigator and included height-
and weight measurements. Blood samples were drawn
by a trained technician between 6:45 a.m. and 8:20 a.m.
at baseline and between 7:00 a.m. and 10:30 a.m. after
the intervention. The blood samples were transported to
the hospital laboratory on dry ice, centrifuged and
stored at -80°C until analysed. The participants were
asked to provide the semen sample by masturbating into
a plastic container after at least 48 hours of sexual absti-
nence. They were instructed to keep the container close
to the body, during transportation to the mobile labora-
tory on the weight loss centre to avoid cooling, and one
trained medical laboratory technician performed all
initial semen analyses within one hour after collection.
Furthermore, before and after the weight loss program,
the participants completed questionnaires on their
reproductive experience, medical (e.g. history of diseases
in the reproductive organs) and lifestyle factors (e.g.
smoking status and alcohol consumption) as well as
time and date of the preceding ejaculation, and spillage
(if any) during semen sample collection. Finally, testis
volume was measured by ultrasound of the testes at
baseline by a trained person under the supervision of a
medical doctor.
The men received no incentives, and participation was
conditional on written informed consent. The regional
ethics committee approved the study (reg. number
20060039).
Analyses of serum samples
Serum samples for testosterone, estradiol, follicle-stimu-
lating hormone (FSH) and luteinizing hormone (LH)
were analysed at the Department of Clinical Biochemis-
try, Aarhus University Hospital, Denmark by Avida Cen-
taur (Bayer Healthcare, Leverkusen, Germany). The sex
hormone-binding globulin (SHBG) concentrations were
determined using IMMULITE (DPC, Koege, Denmark).
Serum concentrations of AMH were measured at the
Laboratory of Reproductive Biology, University Hospital
of Copenhagen, University of Copenhagen, Denmark
using specific ELISA kits according to the manufac-
turer’s instructions (DSL-10-14400; Diagnostic System
Laboratories Inc., Webster, TX, USA). Detection limit
was 0.05 ng/ml and inter- and intra-assay variations
were < 10%. Serum concentrations of Inh-B were mea-
sured at the Laboratory of Reproductive Biology, Uni-
versity Hospital of Copenhagen, Denmark using a
specific ELISA-kit according manufactures instructions
(The Oxford Bio-innovation kit; Biotech-IgG, Copenha-
gen, Denmark).
Analyses of semen samples
Semen volume was estimated by weight (1 g = 1 mL).
Sperm concentration and sperm motility were assessed
as described in ‘WHO Laboratory Manual for the Exam-
ination of Human Semen-Cervical Mucus Interaction’
(World Health Organization, 1999). Analysis of 96% of
the samples was initiated within one hour after ejacula-
tion, and within this time it has been shown that the
sperm motility is stable [44]. Sperm morphology was
assessed using the Tygerberg strict criteria [45]. The
laboratory took part in the European Society for Human
Reproduction and Embryology external quality control
(EQC) program and control tests were in accordance
with results obtained by expert examiners within the
EQC program.
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After semen analysis, 100 μLo ft h er a ws e m e ns a m p l e
was frozen at -80°C for later analysis of sperm DNA
integrity. Sperm DNA integrity was analysed by the flow
cytometric-based sperm chromatin structure assay
(SCSA) at the Reproductive Medicine Centre, Skanes
University Hospital, Malmö, Sweden. The details of this
analysis have previously been described in detail [46,47].
In brief, the SCSA is based on the fact that damaged
chromatin denatures when exposed to an acid-detergent,
whereas normal double-stranded chromatin remains
stable. After blue-light excitation, the SCSA measures
the denaturation of sperm DNA with the dye acridine
orange, which differentially stains double- and single-
stranded nucleic acids. Five thousand cells were analysed
by FACSort (Becton Dickinson, San Jose, CA, USA).
Analysis of the flow cytometric data was carried out
using dedicated software (SCSASoft; SCSA Diagnostics,
Brookings, SD, USA.). The percentage of abnormal
sperm with detectable DFI (%DFI) was calculated from
the DFI frequency histogram. For the flow cytometer
set-up and calibration, a reference sample was used
from a normal donor ejaculate sample retrieved from
the laboratory repository. The intra-laboratory coeffi-
cient of variation for DFI analysis was found to be 4.5%.
One investigator blinded to the exposure and other co-
variates performed the analyses.
Statistical analyses
In the cross-sectional study, three groups were formed
according to BMI at baseline (1: 33.3 to 41.6 kg/m
2,2 :
41.7 to 46.08 kg/m
2 a n d3 :4 6 . 1t o6 0 . 9k g / m
2). In the
longitudinal study, we calculated the percentage weight
loss and formed three groups according to percentage
weight loss (I: 3.5 to 12.1%, II: 12.2 to 17.1% and III:
17.2 to 25.4%).
Outcome variables included reproductive hormones
(testosterone, estradiol, FSH, LH SHBG, AMH and Inh-
B as well as the calculated the calculated free androgen
index (FAI), the free testosterone⁄free estradiol ratio and
LH/free testosterone ratio), conventional semen charac-
teristics (semen volume, sperm concentration, total
sperm count, sperm motility and sperm morphology)
and DFI. In the longitudinal study, the outcome vari-
ables included the differences in the parameters men-
tioned above.
For each of the outcome variables, crude median, 25
th,
and 75
th percentiles were calculated. We performed
multiple linear regression analyses with BMI and per-
centage weight loss as the main determinants. Low
BMI/percentage weight loss was considered the refer-
ence category. When we tested for trend, BMI and per-
centage weight loss was entered as a continuous
explanatory variable.
In the cross-sectional study, data on the semen char-
a c t e r i s t i c s ,a sw e l la sL H ,F S H ,A M H ,I n h - B ,t h ef r e e
testosterone/free estradiol ratio, LH/free testosterone
ratio and testis volume were transformed logarithmically
to obtain an approximate linear distribution of residuals,
whereas no transformations were used on data in the
longitudinal study. In the longitudinal study, differences
in semen characteristics and reproductive hormones
from baseline to follow-up were calculated by subtract-
ing the second sample value from the first sample value,
t h u sap o s i t i v ed i f f e r e n c ec o r r e s p o n d st oar i s ei nt h e
characteristics from baseline to follow-up.
A priory, we decided which covariates that potentially
should be included in the models, and due to the sam-
ple size, we based the selection on a 5% change-in-esti-
mate principle [48]. In the cross-sectional study, the
following potential confounders were considered for the
regression analyses (see table 1): smoking (yes or no),
history of diseases in reproductive organs (cryptorchid-
ism, testicular cancer, surgery in urogenital organs,
orchitis and chlamydia infection combined into one
variable, present, not present or unknown), season of
blood- or semen sampling (April to September or Octo-
ber to March) and age at blood- or semen sampling
(continuous). For the analyses on semen characteristics,
we also considered the period of abstinence time (< 48
hours, 2 - 5 days or > 5 days), spillage at semen sam-
pling (yes or no) and for analysis of motility also min-
utes from ejaculation to analysis (continuous).
Furthermore, for the regression analyses of reproductive
hormones we also considered recent fever.
In the longitudinal study, the following potential con-
founders were considered (see table 2): differences in
smoking status (no difference, smoker at the first sam-
ple, but not at the second sample or smoker at the sec-
ond sample, but not at the first sample) and difference
in season (no difference in season, September - April at
the first sample and March - October at the second
sample or March - October at the first sample and Sep-
tember - April at the second sample). In the semen ana-
lyses, the differences in spillage (no difference, spillage
at the first sample and not at the second sample or spil-
lage at the second sample and not at the first sample)
and the differences in abstinence time (days) were addi-
tionally considered, and for analysis of motility, the dif-
ferences in minutes from sampling to analysis. In the
statistical analyses on semen volume and total sperm
count, the men reporting spillage were excluded from
the analyses.
We performed sub-analyses to check consistency of
our results, using differences in BMI as the explanatory
variable instead of weight loss in percent. Finally, due to
the low number of participants in the analyses of semen
volume and total sperm count after exclusion of
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Parameter Body mass index (BMI), kg/m
2 Test for trend*
33.3 - 41.6
(n = 14)
#
41.7 - 46.08
(n = 14)
#
46.1 - 60.9
(n = 15)
#
P-value
Sperm concentration (millions/ml)
Median (p25, 75) 54 (25, 102) 24 (4, 55) 19 (8, 33) 0.03
Adjusted back-transformed median (95% CI)
a, b, d 18 (3, 111) 4 (1, 28) 5 (1, 39) 0.02
Semen volume (ml)
Median (p25, 75) 2.9 (2.2, 4.0) 3.5 (2.2, 5.8) 3.3 (2.4, 4.0) 0.92
Adjusted back-transformed median (95% CI)
a, b, c, d, e 1.7 (0.8, 3.5) 2.6 (1.3, 5.4) 1.7 (0.7, 4.1) 0.74
Total sperm count (millions)
Median (p25, 75) 209 (62, 230) 93 (11, 204) 46 (22, 76) 0.03
Adjusted back-transformed median (95% CI)
a, e 70 (32, 156) 31 (11, 90) 23 (9, 56) 0.02
Normal sperm morphology (%)
Median (p25, 75) 9 (6, 11) 5 (2, 13) 5 (1, 9) 0.28
Adjusted back-transformed median (95% CI)
a, c, d, e 10 (0, 244) 7 (0, 103) 2 (0, 61) 0.04
Motile sperm (%)
Median (p25, 75) 73 (64, 77) 57 (43, 71) 55 (40, 67) 0.06
Adjusted back-transformed median (95% CI)
h 59 (21, 163) 46 (16, 132) 19 (7, 51) 0.005
DNA fragmentation index, DFI (%)
Median (p25, 75) 10 (7, 18) 16 (12, 32) 18 (12, 23) 0.23
Adjusted back-transformed median (95% CI)
a, b, d, e, f 9 (4, 19) 12 (6, 25) 10 (4, 24) 0.70
Testosterone (nmol/L)
Median (p25, 75) 9.2 (7.8, 11.4) 8.0 (6.4, 11.0) 7.0 (6.0, 8.0) 0.005
Adjusted mean (95% CI)
b, d, e, g 8.7 (5.3, 12.2) 9.1 (6.0, 12.2) 6.3 (2.6, 10.1) 0.04
Estradiol (nmol/L)
Median (p25, 75) 0.10 (0.09, 0.15) 0.15 (0.14, 0.17) 0.19 (0.16, 0.23) < 0.005
Adjusted mean (95% CI)
b, d, e, g 0.11 (0.07, 0.16) 0.13 (0.09, 0.17) 0.18 (0.13, 0.23) < 0.005
SHBG (nmol/L)
Median (p25, 75) 18.0 (12.4, 22.7) 17.4 (14.7, 25.0) 22.8 (15.2, 27.5) 0.62
Adjusted mean (95% CI)
b, d, e, g 20.5 (13.0, 27.9) 21.5 (14.9, 28.1) 24.2 (16.1, 32.3) 0.07
FSH (IU/L)
Median (p25, 75) 2.8 (2.6, 3.7) 4.5 (2.2, 5.9) 3.2 (2.2, 3.4) 0.36
Adjusted back-transformed median (95% CI)
b, d, e, g 2.8 (1.7, 4.6) 3.9 (2.5, 6.2) 2.2 (1.3, 3.9) 0.30
LH (IU/L)
Median (p25, 75) 3.6 (2.9, 4.6) 4.9 (3.7, 6.8) 3.9 (2.8, 5.2) 0.86
Adjusted back-transformed median (95% CI)
b, d, e, g 3.1 (2.0, 4.8) 4.7 (3.1, 7.0) 2.9 (1.8, 4.8) 0.60
Inhibin B (pg/ml)
Median (p25, 75) 160 (141, 220) 123 (117, 170) 120 (86, 171) 0.004
Adjusted back-transformed median (95% CI)
d, e 156 (94, 257) 128 (84, 195) 110 (64, 188) 0.04
AMH (ng/ml)
Median (p25, 75) 3.6 (3.1, 4.3) 2.9 (1.8, 4.0) 3.3 (2.2, 4.9) 0.60
Adjusted back-transformed median (95% CI)
b, d, e, g 2.8 (1.7, 4.7) 2.3 (1.5, 3.7) 2.5 (1.4, 4.3) 0.68
Free androgen index (FAI)
Median (p25, 75) 59.1 (43.2, 75.8) 45.3 (38.9, 62.8) 33.4 (28.7, 44.0) 0.008
Adjusted back-transformed median (95% CI)
b, d, e, g 55.0 (36.3, 73.6) 46.3 (29.7, 62.8) 28.5 (8.3, 48.7) < 0.005
Free testosterone/free estradiol ratio
Median (p25, 75) 95.2 (76.8, 108.4) 56.2 (45.8, 82.8) 35.6 (32.0, 56.1) < 0.005
Adjusted median (95% CI)
b, d, g 69.4 (45.7, 105.2) 59.5 (40.0, 88.3) 32.5 (20.8, 51.0) < 0.005
LH/free testosterone ratio
Median (p25, 75) 0.07 (0.06, 0.09) 0.10 (0.08, 0.11) 0.10 (0.08, 0.17) 0.005
Adjusted back-transformed median (95% CI)
b, d, e, g 0.07 (0.04, 0.10) 0.11 (0.07, 0.17) 0.11 (0.06, 0.18) 0.009
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lyses with all participants included and adjusted for spil-
lage instead. In one model, we adjusted for the
covariates by using the difference (e.g. difference in spil-
lage) from baseline to follow up, as described above.
Additionally, we fitted a model with total sperm count
at follow-up as a function of the weight loss, controlling
for total sperm count at baseline as well as the other
covariates (spillage, abstinence time and season).
The statistical analyses were performed by using Stata
11 software (Stata Corporation, Cillege Station, TX). A
two-tailed P value of < 0.05 was considered statistically
significant.
Results
The median (range) age was 32 (20-59) years. The med-
ian (range) BMI was 44 (33 - 61) kg/m
2.I nt a b l e1 ,t h e
semen characteristics and reproductive hormone levels
at baseline according to BMI are presented. After
adjustment for potential confounders, BMI was inversely
associated with sperm concentration, total sperm count,
normal sperm morphology, and motile sperm. The
group with the highest BMI had a 71% (95% CI: -6; 92)
lower sperm concentration and 68% (95% CI: 14; 88)
lower total sperm count than the group with the lowest
BMI. For semen volume and DFI, no statistically signifi-
cant trends were observed, however, the median DFI
tended to increase with higher levels of BMI. Further-
more, BMI was negatively associated with testosterone
and Inh-B and positively associated with estradiol at
baseline. The calculated FAI and free testosterone⁄free
estradiol ratio were lower at higher levels of BMI. The
data indicated a higher level of SHBG with higher levels
of BMI, although not statistically significant. There was
no difference in testis volume in the groups (Table 1).
Following the weight loss program, the median (range)
weight loss was 22 (4; 39) kg, corresponding to a med-
ian percentage weight loss on 15%, ranging from 3.5%
to 25.4%. In table 2, the adjusted mean (95% CI) differ-
ences in semen characteristics and reproductive hor-
mone levels according to weight loss in percent are
presented. After adjustment, the percentage weight loss
was positively associated with an increase in total sperm
count and semen volume. The group with the largest
weight loss had a statistically significant increase in both
total sperm count [193 millions (95% CI: 45; 341)] and
morphology [4% (95% CI: 1; 7)]. We observed no differ-
ence in DFI from baseline to follow-up. When using the
differences in BMI instead of percentage weight differ-
ence as the explanatory variable, the direction and mag-
nitude of the associations were essentially unchanged.
Additionally, the percentage weight loss was associated
with an increase in testosterone, SHBG and AMH, and
FAI and the free testosterone/free estradiol ratio tended
to increase with increasing weight loss in percent.
Finally, the results from the sub-analyses with semen
volume and total sperm count with all participants were
in the same direction, however, attenuated as expected,
and p-values were no longer below 0.05.
Discussion
The study showed that a high BMI at baseline was asso-
ciated with low values of total sperm count, sperm con-
centration, normal sperm morphology, and motile
sperm. Weight loss was associated with an increase in
total sperm count and semen volume among men who
participated in a 14-week weight loss program. Addi-
tionally, the weight loss was associated with an increase
in testosterone, SHBG and AMH, and FAI improved
significantly in the group with the largest weight reduc-
tion. Weight loss did not decrease serum estradiol levels.
As far as we know, this is the first cohort study inves-
tigating the association between weight loss and semen
quality. Thus the results are unchallenged and further
research is necessary to disclose the matter further. Our
results indicate that there is a causal inverse association
between BMI and semen quality, and that it may be
possible to improve semen quality by a weight reduc-
tion. However, we cannot exclude that changes in life-
style, diet or exercise caused the observed improvement
in semen quality, rather than the reduction in weight
per se.
Despite conflicting results [15-21], previous studies (all
cross-sectional) have mainly shown low sperm
Table 1 Semen characteristics and reproductive hormone levels at baseline according to body mass index (BMI)
(Continued)
Testis volume (ml)
Median (p25, 75) 13.5 (11.0, 14.0) 10.0 (8.0, 17.5) 12.0 (10.0, 15.0) 0.80
Adjusted back-transformed median (95% CI)
a, d, e 8.5 (4.0, 18.5) 8.0 (4.0, 16.0) 10.0 (4.0, 24.0) 0.98
p, percentile; CI, confidence interval. *Trends were tested by Spearman’s rank correlation test and multiple linear regression analyses with BMI entered as a
continuous explanatory variable. #This number of participants (n) relates to the hormone parameters except for AMH. The numbers in the groups for the
following variables are: sperm concentration n = 13, n = 14, n = 14; semen volume n = 13, n = 8, n = 9; total sperm count n = 13, n = 7, n = 10; morphology n
= 12, n = 14, n = 14; motility n = 13, n = 14, n = 14; DFI n = 11, n = 14, n = 14; testis volume: n = 5, n = 9, n = 7, AMH n = 13, n = 13, n = 15.
The medians are adjusted for the following: abstinence time (a), current smoking (b), season (c), diseases in the reproductive organs (d), age (e), spillage at
semen sampling (f) fever (g) and minutes from ejaculation to start of semen analysis (h).
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[5,8,9,11,12,49], similar to what we find. Considering the
well-established association between male obesity and
altered reproductive hormonal profile, and the fact that
testosterone is required in large concentrations to main-
tain spermatogenesis, it is reasonable to consider obesity
to also affect semen quality. Thus we believe that the
inverse association between BMI and semen quality is
not a chance finding.
The hormonal profile among obese men evaluated in
this study was characterized by abnormalities in the sex
hormones, and weight loss improved some of the hor-
mone levels, however, they were not normalized. It
should be noted that the men were severely obese at
baseline and remained overweight or obese after the
weight loss program. This could explain why we did not
observe a larger improvement in the hormonal para-
meters. The previous published studies, reporting
improvement or normalization of the reproductive hor-
mones, were on less obese men than in this present
study.
Inh-B and AMH are produced almost exclusively by
the Sertoli cells and have been proposed as markers of
spermatogenesis. Inh-B have been found to be signifi-
cantly lower in men with testicular dysfunction [34-36]
and AMH to be significantly lower in subfertile men
[38-40]. Therefore, we expected both hormones to be
negatively associated with BMI, but this was only seen
for Inh-B, as previously reported [16]. In this present
study we compared severely obese men, all with BMI
above 30 kg/m
2 when entering the study and the AMH
levels among these men might be lower than normal
weight men, which could explain why we see no differ-
ence when comparing the two groups with the most
obese men with the least obese men. Tüttelmann et al.
[43] showed that, among men with a median BMI of
25.7 kg/m
2, the median (range) concentration of AMH
was 6.3 ng/mL (1.8; 26.8), higher than among the men
in our study where the median (range) AMH concentra-
tion was 3.3 ng/mL (0.2; 10.7). Furthermore, we
hypothesized that Inh-B and AMH would improve by
weight loss but only AMH increased significantly.
The major strength of this study is the successful
weight loss program, providing prospectively collected
data, which adds new important information to the
existing cross-sectional studies. The risk of misclassifica-
tion of the outcome variables is limited and most likely
non-differential, since analyses of semen and blood sam-
ples were performed blinded to the exposure variables.
Misclassification of the exposure variables is unlikely
since anthropometric measurements were obtained on-
site by one investigator and do not depend on self-
reports. From the questionnaires, data were available on
the main factors that we think affect semen quality,
such as abstinence time and diseases of the reproductive
organs. However, confounding from other unknown fac-
tors is possible and our findings may also be due to
chance, since the sample size is small.
Table 2 Differences in semen characteristics and reproductive hormone levels according to weight loss
Adjusted mean (95% CI) differences in semen and hormone levels Weight loss in percent (%) Test for trend*
3.5 - 12.1
(n = 10
#)
12.2 - 17.1
(n = 10
#)
17.2 - 25.4
(n = 10
#)
P-value
Sperm concentration (millions/ml)
a, c, d -11 (-49, 27) 19 (-23, 61) 17 (-24, 58) 0.33
Semen volume (ml)
c -1.0 (-2.3, 0.3) 1.5 (-0.4, 3.5) 1.3 (-0.9, 3.4) 0.04
Total sperm count (millions)
a, c -41 (-147, 65) 232 (77, 387) 193 (45, 341) 0.02
Normal sperm morphology (%)
a, b, c 0 (-2, 4) 1 (-3, 4) 4 (1, 7) 0.16
Motile sperm (%)
a, c, d, e -2 (-15, 11) 4 (-10, 18) 11 (-3, 25) 0.22
DFI (%)
a, b, c, d 7 (-2, 17) -1 (-11, 9) 0 (-10, 10) 0.96
Testosterone (nmol/L)
a, b 0.7 (-1.1, 2.5) 3.3 (1.4, 5.2) 3.7 (2.0, 5.4) 0.02
Estradiol (nmol/L) -0.03 (-0.05, 0) -0.02 (-0.05, 0) -0.01 (-0.03, 0.01) 0.93
SHBG (nmol/L)
a, b 1.7 (-2.2, 5.5) 5.0 (1.0, 9.0) 5.0 (1.4, 8.5) 0.03
FSH (iu/L)
a 0.1 (-0.3, 0.6) 0.3 (-0.3, 0.8) 0.1 (-0.3, 0.6) 0.95
LH (iu/L)
a, b 0.7 (-0.6, 2.0) 1.2 (-0.1, 2.6) 0.3 (-0.9, 1.5) 0.85
Inhibin B (pg/ml)
a, b -30.1 (-51.7, -8.4) -22.3 (-44.8, 0.2) -13.6 (-33.6, 6.4) 0.34
AMH (ng/ml)
a, b -0.29 (-0.65, 0.07) -0.02 (-0.42, 0.38) 0.24 (-0.09, 0.59) 0.02
Free androgen index (FAI)
a, b -3.7 (-13.3, 6.0) 3.5 (-6.5, 13.6) 6.5 (-2.4, 15.4) 0.43
Free testosterone/free estradiol ratio
a 15.0 (0.5, 29.4) 38.3 (22.1, 54.4) 25.7 (11.4, 40.0) 0.18
CI, confidence interval. *Trends were tested by multiple regression analyses with weight loss in percent entered as a continuous explanatory variable. #This
number of participants (n) relates to the differences in hormone parameters, except for AMH. The numbers in the groups for the following variables are: sperm
concentration n = 9, n = 9, n = 9; semen volume n = 7, n = 4, n = 4; total sperm count n = 6, n = 4, n = 4; morphology n = 9, n = 9, n = 9; motility n = 8, n = 9,
n = 9, DFI n = 8, n = 9, n = 9 and AMH n = 10, n = 9, n = 10
The means are adjusted for the following: difference in season (a), difference in smoking status (b), difference in abstinence time (c), difference in spillage at
semen sampling (d) and difference in minutes from ejaculation to start of semen analysis (e).
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Page 6 of 8The major limitation in this study is the limited sam-
ple size, resulting in wide confidence intervals, and the
results must therefore be interpreted with caution. The
participation rate (41%) is low, and leaves open the pos-
sibility of selection among participants. However, to
cause bias away from the null, selection has to be
related to both semen quality and BMI, and the partici-
pation rate of men with poor semen quality and high
BMI must be higher. We have no reason to suspect par-
ticipation to be associated with the exposure and the
risk of differential participation and selection bias is lim-
ited, although it is possible as a chance phenomenon.
Furthermore, loss to follow-up leaves room for selection
bias, if attrition is dependent on the change in semen
quality as well as related to the weight loss. Therefore,
we examined if those who dropped out of the study sys-
tematically differed from those who remained in the
sample. The two groups were found to have similar
weight, BMI and reproductive hormones at baseline.
Sperm concentration and total sperm count were lower
among loss to follow-up men than among those who
remained and the direction of this selection bias could
be both away and toward the null.
Finally, the follow-up period was on average 103 days
(ranging from 86 to 111 days), and spermatogenesis
takes approximately 64 days [50]. Thus the follow-up
p e r i o di nt h ep r e s e n ts t u d ys h o u l db ea b l et od e t e c t
changes on the early stages of spermatogenesis, although
a longer follow-up period would be desirable.
Thirty-four percent of the men had sperm concentra-
tions below the World Health Organization (2010) refer-
ent level of 15 million/ml when entering the study. The
median (p25, 75) sperm concentration of all participants
at baseline was 25 (12, 64) million/ml and 19 (8, 33)
million/ml among the most obese men. Since fecundity
increases with sperm concentrations up to approxi-
mately 40 million/mL [51], some may have problems
fathering a child.
Conclusions
To conclude on this pilot cohort study, we observed
that the altered androgen profile tended to improve fol-
lowing weight loss and that weight loss may potentially
lead to improvement in semen quality, although we can
not conclude this to be a result of the reduction in body
weight per se. The observation has biologic plausibility,
but the findings should be replicated in a larger cohort
with longer follow-up time including a wider range of
BMI levels.
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